Oric Pharmaceuticals (ORIC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Oric Pharmaceuticals (ORIC) is Neutral.

The composite score behind that read is -0.06, weighing +0.00 of bullish evidence against -0.30 bearish.

Oric Pharmaceuticals last closed at $11.99, -0.33% on the session.

Against the IVW growth benchmark the position is -1.13% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for ORIC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Oric Pharmaceuticals in the 22nd percentile on return on equity, where 100 is best.

Oric Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $1.25B.

StockMap tracks Oric Pharmaceuticals as the 121st largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Oric Pharmaceuticals ranks 169th of 381 in the group, against a group median of -0.08.